EGR1 and diabetes mellitus: Thus, MOTS-c not only inhibits the development of diabetes and attenuates diabetic myocardial lesions by multiple pathways, including attenuation of mitophagy, reducing mitochondrial damage, and inhibiting myocardial apoptosis through the CCN1/ERK/EGR1 pathway, as illustrated in Figure 8.